RT Journal Article
T1 Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching study.
A1 Boada, Aram
A1 Tejera-Vaquerizo, Antonio
A1 Ribero, Simone
A1 Puig, Susana
A1 Moreno-Ramírez, David
A1 Descalzo-Gallego, Miguel A
A1 Fierro, María T
A1 Quaglino, Pietro
A1 Carrera, Cristina
A1 Malvehy, Josep
A1 Vidal-Sicart, Sergi
A1 Bennássar, Antoni
A1 Rull, Ramón
A1 Alos, Llucìa
A1 Requena, Celia
A1 Bolumar, Isidro
A1 Traves, Víctor
A1 Pla, Ángel
A1 Fernández-Figueras, María T
A1 Ferrándiz, Carlos
A1 Pascual, Iciar
A1 Manzano, José L
A1 Sánchez-Lucas, Marina
A1 Giménez-Xavier, Pol
A1 Ferrandiz, Lara
A1 Nagore, Eduardo
K1 melanoma
K1 prognosis
K1 propensity score
K1 sentinel lymph node biopsy
AB The clinical value of sentinel lymph node (SLN) biopsy in thick melanoma patients (Breslow >4 mm) has not been sufficiently studied. The aim of the study is to evaluate whether SLN biopsy increases survival in patients with thick cutaneous melanoma, and, as a secondary objective, to investigate correlations between survival and lymph node status. We included 1,211 consecutive patients with thick melanomas (>4 mm) registered in the participating hospitals' melanoma databases between 1997 and 2015. Median follow-up was 40 months. Of these patients, 752 were matched into pairs by propensity scores based on sex, age, tumor location, histologic features of melanoma, year of diagnosis, hospital and adjuvant interferon therapy. The SLN biopsy vs. observation was associated with better DFS [adjusted hazard ratio (AHR), 0.74; 95% confidence interval (CI) 0.61-0.90); p = 0.002] and OS (AHR, 0.75; 95% CI, 0.60-0.94; p = 0.013) but not MSS (AHR, 0.84; 95% CI, 0.65-1.08; p = 0.165). SLN-negative patients had better 5- and 10-year MSS compared with SLN-positive patients (65.4 vs. 51.9% and 48.3 vs. 38.8%; p = 0.01, respectively). As a conclusion, SLN biopsy was associated with better DFS but not MSS in thick melanoma patients after adjustment for classic prognostic factors. SLN biopsy is useful for stratifying these patients into different prognostic groups.
YR 2017
FD 2017-10-13
LK http://hdl.handle.net/10668/11622
UL http://hdl.handle.net/10668/11622
LA en
DS RISalud
RD Apr 6, 2025